Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;36(6):653-662.
doi: 10.14670/HH-18-340. Epub 2021 Apr 15.

Hepatic Macrophage activation and the LPS pathway in patients with different degrees of severity and histopathological patterns of drug induced liver injury

Hui-Juan Du #  1 , Su-Xian Zhao #  1 , Wen Zhao  1 , Na Fu  1 , Wen-Cong Li  1 , Xiao-Jie Qin  1 , Yu-Guo Zhang  1 , Yue-Min Nan  2 , Jing-Min Zhao  3
Affiliations

Hepatic Macrophage activation and the LPS pathway in patients with different degrees of severity and histopathological patterns of drug induced liver injury

Hui-Juan Du et al. Histol Histopathol. 2021 Jun.

Abstract

Background: Inflammatory activation of hepatic macrophages plays a primary role in drug-induced liver injury (DILI). However, the exact mechanism underlying DILI remains unclear.

Methods: A total of 328 DILI patients and 80 healthy individuals were prospectively enrolled in this study. The DILI patients were categorized into subgroups based on either disease severity or histopathological patterns. Plasma soluble CD163 (sCD163) and hepatic CD163 were examined to determine hepatic macrophage activation, and CD8, CD20, and MUM-1 were assessed to determine cellular immunity using immunohistochemistry. The lipopolysaccharide (LPS) pathway proteins [e.g. LPS, soluble CD14 (sCD14), and LPS-binding protein (LBP)] were measured using enzyme-linked immunosorbent assay.

Results: Plasma sCD163 levels were nine-fold higher in DILI patients than in healthy controls at the baseline, but significantly decreased at the 4-week follow-up visit after treatment. The numbers of hepatic macrophages, B cells, and plasma cells were significantly higher in the liver tissues from DILI patients than those from healthy controls. Furthermore, the baseline levels of LPS pathway proteins in the DILI patients were significantly higher than those in the controls. Notably, these proteins significantly decreased at the 4-week follow-up visit but remained significantly higher than the levels for the controls.

Conclusions: Hepatic inflammation in DILI involves the activation of hepatic macrophages and cellular immunity, in which the LPS pathway likely plays a role, at least in part. As such, this study has improved our understanding of the pathological mechanisms for DILI and may facilitate the development of better treatments for patients with DILI.

PubMed Disclaimer

References

    1. Aiso M., Takikawa H., Tsuji K., Kagawa T., Watanabe M., Tanaka A., Sato K., Sakisaka S., Hiasa Y., Takei Y., Ohira H., Ayada M., Hashimoto E., Kaneko S., Ueno Y., Ohmoto K., Takaki A., Torimura T., Matsuzaki Y., Tajiri K., Yoneda M., Ito T., Kato N., Ikejima K., Mochida S., Yasuda H. and Sakamoto N. (2019). Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan. Hepatol. Res. 49, 105-110. - PubMed
    1. Andrade R.J., Chalasani N., Bjornsson E.S., Suzuki A., Kullak-Ublick G.A., Watkins P.B., Devarbhavi H., Merz M., Lucena M.I., Kaplowitz N. and Aithal G.P. (2019). Drug-induced liver injury. Nat. Rev. Dis. Primers. 5, 58. - PubMed
    1. Dhillon A.K., Kummen M., Troseid M., Akra S., Liaskou E., Moum B., Vesterhus M., Karlsen T.H., Seljeflot I. and Hov J.R. (2019). Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis. Liver Int. 39, 371-381. - PubMed
    1. Eming S.A., Wynn T.A. and Martin P. (2017). Inflammation and metabolism in tissue repair and regeneration. Science 356, 1026- 1030. - PubMed
    1. European Association for the Study of the Liver. Electronic address e. e. e., Clinical Practice Guideline Panel C., Panel m. and representative E.G.B. (2019). EASL Clinical Practice Guidelines: Drug-induced liver injury. J. Hepatol. 70, 1222-1261. - PubMed

MeSH terms